About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
REGN - Regeneron Pharmaceut...| Previous Close | $598.86 | Open | $599.90 |
| Volume | 320.1K | Market Cap | 64.712B |
| Yield | Last Dividend |
| Regeneron Pharmaceuticals : Gets FDA Pri... | 6:47 AM |
| By Colin Kellaher Regeneron Pharmaceuticals Inc. on Wednesday said the U.S. Food and Drug Administration granted priority review to its biologics lice... | |
| Regeneron???s Covid-19 Treatment Could B... | 08/10/20 |
| Biotech Regeneron Pharmaceuticals has a cocktail of antibodies for treating Covid-19. Cannacord analyst John Newman says the treatment is ???critical?... | |
| Regeneron profit beats on Dupixent stren... | 08/05/20 |
| Regeneron Pharmaceuticals Inc beat second-quarter profit estimates on Wednesday, spurred by higher sales of its blockbuster eczema treatment Dupixent,... | |
| Regeneron Pharma posts quarterly profit ... | 08/05/20 |
| https://www.investing.com/news/stock-market-news/regeneron-pharma-posts-quarterly-profit-on-228-million-gain-2254232 | |
| Earnings Scheduled For August 5, 2020 | 08/05/20 |
| Companies Reporting Before The Bell ??? AmerisourceBergen Inc. (NYSE: ABC ) is expected to report quarterly earnings at $1.56 per share on revenue of ... | |
| Regeneron: Covid-19 Antibody Combo Preve... | 08/04/20 |
| Regeneron Pharmaceuticals Inc (REGN) has revealed that its investigational COVID-19 antibody drug combination REGN-COV2 both prevented and treated the... | |
| Regeneron Says Its Coronavirus Antibody ... | 08/03/20 |
| Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) said Monday that a non-peer-reviewed study indicated its antibody drug combination both prevented and tr... | |
| Regeneron said COVID-19 combination it i... | 08/03/20 |
| Reuters with the news from Regeneron Pharmaceuticals on Monday - The firm say that the COVID-19 antibody drug combination it is developing both preven... | |
| Regeneron Pharmaceuticals : says antibod... | 08/03/20 |
| Regeneron Pharmaceuticals Inc said on Monday that the COVID-19 antibody drug combination it is developing both prevented and treated the disease in rh... | |
| Regeneron Pharmaceuticals : Eli Lilly st... | 08/03/20 |
| U.S. drugmaker Eli Lilly & Co is beginning a late-stage trial to study whether one of its experimental COVID-19 antibody treatments can prevent the sp... | |
| Global Aplastic Anemia Pipeline Insights... | 07/27/20 |
| DUBLIN--(BUSINESS WIRE)--The "Aplastic Anemia Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Ou... | |
| SHAREHOLDER ALERT: WeissLaw LLP Investig... | 07/22/20 |
| NEW YORK , July 22, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of... | |
| GOLDMAN SACHS: These 17 trades can help ... | 07/21/20 |
| Goldman Sachs strategist Vishal Vivek is telling investors how to maximize their profits around state and federal elections. Vivek says that some stoc... | |
| The Daily Biotech Pulse: Opko Wins CDC C... | 07/21/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20) Abb... | |
| Credit Suisse Upgrades Gilead On Remdesi... | 07/20/20 |
| The biotech sector is a surefire winner due to a two-pronged benefit from the coronavirus pandemic, according to an analyst at Credit Suisse. Biotechs... | |
| BofA On 3 Coronavirus Vaccine Frontrunne... | 07/17/20 |
| The markets are ready for a steady flow of updates from COVID-19 drug and vaccine developers as the world races to contain the pandemic and bring back... | |
| The Daily Biotech Pulse: Ziopharm Starts... | 07/10/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 9) Affi... | |
| Regeneron shares are up 2% after SunTrus... | 07/09/20 |
| Shares of Regeneron Pharmaceuticals Inc. undefined were up 2.1% in trading on Thursday as SunTrust Robinson Humphrey analysts upgraded the stock to bu... | |
| Inside the 3-decade rise of Regeneron ??... | 07/09/20 |
| Hello, Welcome to Dispensed Daily, your daily dose of healthcare news from Business Insider. Are you new to the newsletter? Sign up here to get this e... | |
| The Daily Biotech Pulse: Intersect ENT J... | 07/08/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) AbbV... | |
| Trump administration's Operation Warp Sp... | 07/07/20 |
| $1.6 billion to Novavax and $450 million to Regeneron Pharmaceuticals. | |
| Regeneron signs US$450 million contract ... | 07/07/20 |
| Regeneron Pharmaceuticals Inc said on Tuesday the U.S. government signed a US$450 million contract with the drugmaker to make and supply its potential... | |
| Regeneron's stock gains on $450 million ... | 07/07/20 |
| Shares of Regeneron Pharmaceuticals Inc. undefined gained 0.9% in premarket trading on Tuesday after the drugmaker said it received $450 million from ... | |
| Regeneron Pharmaceuticals : Embarks on P... | 07/06/20 |
| By Matt Grossman Regeneron Pharmaceuticals Inc. is initiating a Phase 3 trial for its double antibody cocktail to determine whether the cocktail can p... | |
| Regeneron advancing COVID-19 cocktail (N... | 07/06/20 |
| Regeneron Pharmaceuticals (NASDAQ:REGN) initiates a large-scale Phase 3 clinical trial evaluating its double antibody cocktail, REGN-COV2, for the pre... | |
| HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS,... | 07/02/20 |
| SAN FRANCISCO, July 2, 2020 /PRNewswire/ -- Hagens Berman urges longtime shareholders in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to submit thei... | |
| Regeneron, Sanofi halt trial for experim... | 07/02/20 |
| Shares of Regeneron Pharmaceuticals Inc. undefined were down 2.4% and Sanofi's undefined stock declined 1.7% in after-hours trading on Friday after th... | |
| GlobalData : Despite temporary increased... | 06/25/20 |
| 25 Jun 2020 Despite temporary increased drug sales for most big bio/pharma companies, Regeneron Pharmaceuticals falls short of Q1 2020 forecast, says ... | |
| Justice Department Sues Regeneron Over P... | 06/24/20 |
| By Peter Loftus The U.S. Justice Department sued Regeneron Pharmaceuticals Inc., accusing the drugmaker of paying kickbacks to a charitable foundation... | |
| U.S. claims Regeneron paid kickbacks via... | 06/24/20 |
| The U.S. Justice Department on Wednesday sued Regeneron Pharmaceuticals Inc , accusing it of using a charity that helps cover Medicare patients' drug ... | |
| Strong Buy rating | 08/07/20 |
| Credit Suisse maintains Outperform rating and raises Price Target from $716.00 to $725.00 | |
| Hold rating | 08/06/20 |
| Citigroup maintains Neutral rating and raises Price Target from $585.00 to $635.00 | |
| Hold rating | 08/06/20 |
| Morgan Stanley maintains Equal-Weight rating and lowers Price Target from $619.00 to $611.00 | |
| Buy rating | 08/06/20 |
| BMO Capital maintains Market Perform rating and raises Price Target from $525.00 to $626.00 | |
| Strong Buy rating | 07/20/20 |
| Credit Suisse maintains Outperform rating and raises Price Target from $700.00 to $716.00 | |
| Hold rating | 07/15/20 |
| Morgan Stanley maintains Equal-Weight rating and raises Price Target from $555.00 to $619.00 | |
| Buy rating | 07/09/20 |
| SunTrust Robinson Humphrey upgrades from Hold to Buy rating and raises Price Target from $400.00 to $750.00 | |
| Buy rating | 07/08/20 |
| Canaccord Genuity maintains Buy rating and raises Price Target from $660.00 to $700.00 | |
| Strong Buy rating | 07/01/20 |
| Oppenheimer maintains Outperform rating and raises Price Target from $625.00 to $675.00 | |
| Strong Buy rating | 06/24/20 |
| Credit Suisse maintains Outperform rating and raises Price Target from $605.00 to $700.00 | |
| Buy rating | 06/12/20 |
| Jefferies maintains Buy rating and raises Price Target from $657.00 to $691.00 | |
| Strong Buy rating | 05/27/20 |
| and raises Price Target from $622.00 to $625.00 | |
| Hold rating | 05/27/20 |
| CFRA maintains Hold rating and lowers Price Target from $557.00 to $549.00 | |
| Strong Buy rating | 05/26/20 |
| Wells Fargo upgrades from Equal-Weight to Overweight rating and announces Price Target of $734.00 | |
| Date | 2020-08-05 (BMO) | Est. (EPS/Rev.) | $5.98/ 1.74B |
| Actual (EPS/Rev.) | $7.16/ $1.95 B | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Stock_Options | alps | 92.00 % | Follow |
| Spread and Condor Play | Sankar | 65.00 % | Subscribe |
| Potential Trading Ideas | Potential Trading | 59.00 % | Follow |
| Best Trading Ideas | Best Trading Ideas | 53.00 % | Follow |
| TopFlight Trades - Premium (Options) | Eric Cunningham | 52.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
